Ascelia Pharma
3.00 SEK
-1.96 %
Less than 1K followers
ACE
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Valuation
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Ascelia Pharma
P/B
Median 2019-2025
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Share price (SEK) | 16.33 | 39.02 | 20.65 | 10.34 | 2.33 | 2.92 | 3.22 |
| Shares | 33.6 | 41.4 | 48.9 | 50.4 | 50.4 | 97.2 | 126.9 |
| Market cap | 549.2 | 1,615.6 | 1,008.8 | 521.0 | 117.5 | 283.8 | 407.9 |
| Enterprise value | 440.7 | 1,431.8 | 747.8 | 371.9 | 96.7 | 233.9 | - |
| EV/S | - | - | - | - | - | - | - |
| EV/EBITDA | neg. | neg. | neg. | neg. | neg. | neg. | - |
| EV/EBIT | neg. | neg. | neg. | neg. | neg. | neg. | - |
| P/E | neg. | neg. | neg. | neg. | neg. | neg. | neg. |
| P/B | 2.32 | 6.84 | 3.28 | 2.88 | 1.58 | 3.60 | 4.10 |
| P/S | - | - | - | - | - | - | - |
| Dividend yield | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % |
| Equity ratio | 94.7 % | 92.4 % | 92.3 % | 82.7 % | 85.4 % | 56.0 % | 88.9 % |
| Gearing ratio | - | 0.4 % | 0.2 % | 0.3 % | 1.4 % | 32.2 % | 1.0 % |